vs

Side-by-side financial comparison of APi Group Corp (APG) and Steris (STE). Click either name above to swap in a different company.

APi Group Corp is the larger business by last-quarter revenue ($2.0B vs $1.5B, roughly 1.3× Steris). Steris runs the higher net margin — 12.9% vs 2.9%, a 10.0% gap on every dollar of revenue. On growth, APi Group Corp posted the faster year-over-year revenue change (11.7% vs 9.2%). Steris produced more free cash flow last quarter ($199.5M vs $67.0M). Over the past eight quarters, Steris's revenue compounded faster (15.8% CAGR vs 7.0%).

X.AI Corp., doing business as xAI, is an American company working in the area of artificial intelligence (AI), social media and technology that is a wholly owned subsidiary of American aerospace company SpaceX. Founded by Elon Musk in 2023, the company's flagship products are the generative AI chatbot named Grok and the social media platform X, the latter of which they acquired in March 2025.

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.

APG vs STE — Head-to-Head

Bigger by revenue
APG
APG
1.3× larger
APG
$2.0B
$1.5B
STE
Growing faster (revenue YoY)
APG
APG
+2.5% gap
APG
11.7%
9.2%
STE
Higher net margin
STE
STE
10.0% more per $
STE
12.9%
2.9%
APG
More free cash flow
STE
STE
$132.5M more FCF
STE
$199.5M
$67.0M
APG
Faster 2-yr revenue CAGR
STE
STE
Annualised
STE
15.8%
7.0%
APG

Income Statement — Q1 FY2026 vs Q3 FY2026

Metric
APG
APG
STE
STE
Revenue
$2.0B
$1.5B
Net Profit
$57.0M
$192.9M
Gross Margin
31.3%
43.8%
Operating Margin
5.2%
18.3%
Net Margin
2.9%
12.9%
Revenue YoY
11.7%
9.2%
Net Profit YoY
11.2%
EPS (diluted)
$0.12
$1.96

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
APG
APG
STE
STE
Q1 26
$2.0B
Q4 25
$2.1B
$1.5B
Q3 25
$2.1B
$1.5B
Q2 25
$2.0B
$1.4B
Q1 25
$1.7B
$1.5B
Q4 24
$1.9B
$1.4B
Q3 24
$1.8B
$1.3B
Q2 24
$1.7B
$1.3B
Net Profit
APG
APG
STE
STE
Q1 26
$57.0M
Q4 25
$97.0M
$192.9M
Q3 25
$93.0M
$191.9M
Q2 25
$77.0M
$177.4M
Q1 25
$35.0M
$145.7M
Q4 24
$67.0M
$173.5M
Q3 24
$69.0M
$150.0M
Q2 24
$69.0M
$145.4M
Gross Margin
APG
APG
STE
STE
Q1 26
31.3%
Q4 25
32.0%
43.8%
Q3 25
31.3%
44.2%
Q2 25
30.9%
45.1%
Q1 25
31.5%
43.3%
Q4 24
30.9%
44.5%
Q3 24
31.1%
43.6%
Q2 24
31.4%
44.7%
Operating Margin
APG
APG
STE
STE
Q1 26
5.2%
Q4 25
7.7%
18.3%
Q3 25
7.8%
18.2%
Q2 25
7.2%
17.7%
Q1 25
4.9%
14.6%
Q4 24
6.2%
17.9%
Q3 24
7.8%
16.5%
Q2 24
7.3%
14.5%
Net Margin
APG
APG
STE
STE
Q1 26
2.9%
Q4 25
4.6%
12.9%
Q3 25
4.5%
13.1%
Q2 25
3.9%
12.8%
Q1 25
2.0%
9.8%
Q4 24
3.6%
12.7%
Q3 24
3.8%
11.3%
Q2 24
4.0%
11.4%
EPS (diluted)
APG
APG
STE
STE
Q1 26
$0.12
Q4 25
$-1.16
$1.96
Q3 25
$0.20
$1.94
Q2 25
$0.16
$1.79
Q1 25
$0.11
$1.48
Q4 24
$0.05
$1.75
Q3 24
$0.23
$1.51
Q2 24
$0.22
$1.46

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
APG
APG
STE
STE
Cash + ST InvestmentsLiquidity on hand
$645.0M
$423.7M
Total DebtLower is stronger
$2.8B
$1.9B
Stockholders' EquityBook value
$3.5B
$7.2B
Total Assets
$9.0B
$10.6B
Debt / EquityLower = less leverage
0.79×
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
APG
APG
STE
STE
Q1 26
$645.0M
Q4 25
$912.0M
$423.7M
Q3 25
$555.0M
$319.2M
Q2 25
$432.0M
$279.7M
Q1 25
$460.0M
$171.7M
Q4 24
$499.0M
$155.2M
Q3 24
$487.0M
$172.2M
Q2 24
$324.0M
$198.3M
Total Debt
APG
APG
STE
STE
Q1 26
$2.8B
Q4 25
$2.8B
$1.9B
Q3 25
$2.8B
$1.9B
Q2 25
$2.8B
$1.9B
Q1 25
$2.8B
$1.9B
Q4 24
$2.8B
$2.0B
Q3 24
$2.9B
$2.2B
Q2 24
$2.8B
$2.2B
Stockholders' Equity
APG
APG
STE
STE
Q1 26
$3.5B
Q4 25
$3.4B
$7.2B
Q3 25
$3.3B
$7.0B
Q2 25
$3.2B
$7.0B
Q1 25
$3.0B
$6.6B
Q4 24
$3.0B
$6.4B
Q3 24
$3.0B
$6.6B
Q2 24
$2.8B
$6.4B
Total Assets
APG
APG
STE
STE
Q1 26
$9.0B
Q4 25
$8.9B
$10.6B
Q3 25
$8.7B
$10.4B
Q2 25
$8.5B
$10.4B
Q1 25
$8.1B
$10.1B
Q4 24
$8.2B
$10.0B
Q3 24
$8.2B
$10.2B
Q2 24
$8.0B
$10.1B
Debt / Equity
APG
APG
STE
STE
Q1 26
0.79×
Q4 25
0.81×
0.27×
Q3 25
0.84×
0.27×
Q2 25
0.87×
0.27×
Q1 25
0.92×
0.29×
Q4 24
0.93×
0.32×
Q3 24
0.96×
0.33×
Q2 24
1.00×
0.35×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
APG
APG
STE
STE
Operating Cash FlowLast quarter
$85.0M
$298.2M
Free Cash FlowOCF − Capex
$67.0M
$199.5M
FCF MarginFCF / Revenue
3.4%
13.3%
Capex IntensityCapex / Revenue
6.6%
Cash ConversionOCF / Net Profit
1.49×
1.55×
TTM Free Cash FlowTrailing 4 quarters
$680.0M
$917.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
APG
APG
STE
STE
Q1 26
$85.0M
Q4 25
$382.0M
$298.2M
Q3 25
$232.0M
$287.8M
Q2 25
$83.0M
$420.0M
Q1 25
$62.0M
$260.8M
Q4 24
$283.0M
$332.8M
Q3 24
$220.0M
$250.7M
Q2 24
$110.0M
$303.7M
Free Cash Flow
APG
APG
STE
STE
Q1 26
$67.0M
Q4 25
$356.0M
$199.5M
Q3 25
$201.0M
$201.3M
Q2 25
$56.0M
$326.4M
Q1 25
$50.0M
$189.9M
Q4 24
$265.0M
$243.6M
Q3 24
$198.0M
$148.8M
Q2 24
$88.0M
$195.7M
FCF Margin
APG
APG
STE
STE
Q1 26
3.4%
Q4 25
16.8%
13.3%
Q3 25
9.6%
13.8%
Q2 25
2.8%
23.5%
Q1 25
2.9%
12.8%
Q4 24
14.2%
17.8%
Q3 24
10.8%
11.2%
Q2 24
5.1%
15.3%
Capex Intensity
APG
APG
STE
STE
Q1 26
Q4 25
1.2%
6.6%
Q3 25
1.5%
5.9%
Q2 25
1.4%
6.7%
Q1 25
0.7%
4.8%
Q4 24
1.0%
6.5%
Q3 24
1.2%
7.7%
Q2 24
1.3%
8.4%
Cash Conversion
APG
APG
STE
STE
Q1 26
1.49×
Q4 25
3.94×
1.55×
Q3 25
2.49×
1.50×
Q2 25
1.08×
2.37×
Q1 25
1.77×
1.79×
Q4 24
4.22×
1.92×
Q3 24
3.19×
1.67×
Q2 24
1.59×
2.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

APG
APG

Segment breakdown not available.

STE
STE

Servicerevenues$404.7M27%
Consumablerevenues$387.1M26%
Applied Sterilization Technologies$286.6M19%
Capitalequipmentrevenues$272.1M18%
Life Science$145.8M10%

Related Comparisons